Marea Therapeutics

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

3 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Marea Therapeutics Launches with $190M Funding to Combat Adipose Dysfunction

10 months ago talkbio0Tagged Adipose, biotech, Health care facility, Marea Therapeutics, physiopathological

Marea Therapeutics, Adipose Dysfunction, $190M Funding, Biotech, Healthcare

Marea Therapeutics Secures $190M for Cardiometabolic Medicine Development

10 months ago talkbio0Tagged ANGPTL4 gene, cardiometabolic medicine, Cardiovascular Diseases, clinical-stage program, Marea Therapeutics, metabolic dysfunction, Monoclonal Antibodies, Phase 2 trial, Science of genetics

Marea Therapeutics, cardiometabolic medicine, clinical-stage program, genetics, ANGPTL4, monoclonal antibody, phase 2 trial, metabolic dysfunction, cardiovascular disease.